<DOC>
	<DOC>NCT00404274</DOC>
	<brief_summary>GW679769 may affect liver enzymes that metabolize warfarin. This study is designed to test the extent of the GW679769 affect on Warfarin levels in humans.</brief_summary>
	<brief_title>A Study Testing the Effect and Safety of Casopitant (GW679769) While Taking Warfarin in Healthy Human Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Casopitant</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Inclusion criteria: Healthy subjects nonsmoking Females cannot be able to have children Must be able to swallow and retain oral medication Understand and sign the written consent comply with the requirements and restrictions involved in an overnight 30 day confinement in a healthcare setting Exclusion criteria: cannot participate if subject has a clinically relevant abnormality, medical condition, or circumstance that makes them unsuitable for the study per the study doctor. blood donation in excess of 1 pint within 56 days before dosing of medication iron deficiency history of drug or alcohol abuse or dependency within the past 6 months subjects cannot use any nicotinecontaining products within the last 6 months positive for HIV, Hepatitis B or C use of prescription or nonprescription drug(s), herbal or dietary supplements or vitamins with 14 days prior to first dose of study medication consumption of any food or drink containing grapefruit, Seville oranges, kumquats, pomelos (or their juices) within 7 days of the first dose of study medication history of bleeding disorders or excessive bleeding female who has a positive pregnancy test female who is lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>healthy human volunteer</keyword>
	<keyword>GW679769</keyword>
	<keyword>warfarin</keyword>
	<keyword>casopitant</keyword>
</DOC>